Skip to Primary Navigation

Skip to main content

DOJ signals assertive enforcement of life sciences sector at PCC

A photo of two men in protective clothing working in a drug manufacturing facility, one staring at camera.
Photo: Uriel Sinai/Getty Images

Kevin Kinsella

4 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

For compliance professionals attending the annual conference, the takeaway was hard to miss: 2026 will require a more rigorous compliance framework and transparency.

Federal enforcement officials delivered some of their clearest messages yet to the life sciences industry at this year’s Pharmaceutical Compliance Congress (PCC) in McLean, Virginia, signaling that 2026 will bring more aggressive oversight, broader scrutiny, and heightened expectations for corporate accountability.

Speaking to an audience of compliance officers, in‑house counsel,

, , , , , , , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience